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Background. Impulsive behaviour has become increasingly recognised as a neuropsychiatric complication of Parkinson’s disease
(PD). Thought to be a product of compromised cognitive control, the spectrum of impulsive behaviours in PD ranges from
cognitive disinhibition to impulse control disorders (ICDs). Objective. At present, there are no indicators for trait impulsivity in
PD. The objective of the current study was to identify demographic and clinical predictors of susceptibility to trait impulsivity in a
cohort of PD patients. Methods. The current study assessed impulsivity using the Barratt Impulsiveness Scale 11 (BIS-11) in
a cohort of 87 PD patients. General linear models (GLMs) were used to identify clinical and demographic variables predictive of
heightened BIS-11 second-order attentional and nonplanning subscale scores. Results. Male gender, no history of smoking,
postsecondary education, and heightened disease severity were predictive of increased BIS-11 attentional scores (p < 0.05).
Similarly, male gender, after secondary education, and disease severity were predictive of increased BIS-11 nonplanning scores
(p < 0.05). Contrary to previous reports, dopaminergic medication use was not a signiﬁcant determinant of either BIS-11 subscale
scores. Conclusions. Several demographic and clinical variables including male gender, no history of past smoking, after secondary
education, and elevated disease severity are associated with impulsivity in PD.

1. Introduction
In recent times, a variety of impulsive behaviours, often ranging
in severity, have been reported as psychiatric complications
associated with Parkinson’s disease (PD) [1]. As a construct,
impulsivity is broadly deﬁned as the tendency to act prematurely
or without foresight, with little regard for the often-negative
consequences associated with these actions [2].
Previous studies suggest that PD patients display heightened
impulsivity, particularly when taking dopaminergic medication
[1, 3]. In addition to this, PD may impair response inhibition, an
integral element of impulsivity, with PD patients performing

worse on a range of measures of inhibition, including the StopSignal Task [4, 5], Go/No-Go [6], and antisaccade [7].
Impulsivity is thought to underlie several psychiatric disorders described in PD, particularly impulse control disorders
(ICDs) including pathological gambling, compulsive shopping
and eating, and hypersexual behaviours [1, 8, 9]. These behaviours represent extreme manifestations of impulsivity thought to
be provoked by dopamine agonist [10] therapy and identiﬁed
in only 13% of PD patients [11]. Despite the strong association
between impulsivity and ICDs, PD patients may display impulsivity even in the absence of an ICD [8, 12]. Additionally,
impulsivity represents a signiﬁcant risk factor for the onset of
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an ICD, which further suggests that impulsivity in PD can be
represented on a spectrum; beginning with mild cognitive and
motor disinhibition and eventually manifesting as clinically
identiﬁable ICDs [9].
Previous studies have identiﬁed several variables associated with ICDs including male gender [11], cigarette smoking
history [11, 13, 14], dopamine agonist use [11, 13], younger
age of disease onset [14, 15], a history of drug or alcohol abuse
[9, 15], and a novelty-seeking personality [9, 15]. However,
there are no current demographic or clinical indicators of
future impulsivity in PD. Given the strong association between impulsivity and ICDs in addition with the absence of
treatment options for impulsive behaviour, the identiﬁcation
of risk factors for trait impulsivity serves as a valuable clinical
tool in optimising the prevention of impulsivity and, in turn,
the future onset of ICDs.
As such, the present study characterised a heterogeneous
cohort of Western Australian PD patients with the objective of
identifying demographic and clinical predictors for the development of trait impulsivity. Trait impulsivity was assessed using
the Barratt Impulsiveness Scale 11 (BIS-11), which has been used
extensively in PD clinical settings. The BIS-11 is a reliable
measure of trait impulsivity, addressing the complexity of impulsivity as a construct with a three-component conceptualization comprising attentional impulsivity (reduced ability to focus
on the task at hand and racing thoughts), motor impulsivity (the
tendency to act without thinking), and nonplanning impulsivity
(lack of future- or fore-thought) [16]. Previous studies have
shown adequate internal consistency of BIS-11 second-order
attentional and nonplanning subscales with Cronbach’s α of 0.74
and 0.72, respectively [17]. However, internal consistency of the
BIS-11 second-order Motor subscale is below adequate with
a Cronbach’s α of 0.59 [17]. Further, the aim of the current study
was to assess cognitive domains of impulsivity in PD, rather than
motor domains. Therefore, in the current study assessed only
subjects BIS-11 attentional and nonplanning scores.

2. Methods
2.1. Subjects. Eighty-seven home-based PD patients (54 males)
were sequentially recruited from the Movement Disorders Clinic
at the Perron Institute for Neurological and Translational Science
(Perth, Australia) between 2008 and 2015. All patients were
examined by a movement disorder neurologist prior to inclusion
in the study for veriﬁcation of the diagnosis in accordance with
the UK Brain Bank criteria for IPD. All patients were taking
levodopa, and 45 patients were on a dopamine agonist (pramipexole, rotigotine, and apomorphine). For medication dosages,
LEDD was calculated from patient medication dosages as per the
following: LEDD � (regular levodopa dosage) + 0.75 (slow-release
levodopa) + 10 (bromocriptine) + 10 (pergolide) + amantadine.
Fourteen patients had undergone deep brain stimulation
(DBS) therapy. Demographic variables including a history of
smoking and patients’ level of education were also collected.
2.2. Clinical Assessments and Impulsivity Screening. All clinical
assessments were evaluated in the “ON” state. Motor symptoms were evaluated using the MDS-Uniﬁed Parkinson’s
Disease Rating Scale (MDS-UPDRS) Part III and Hoehn and
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Yahr Scale. In addition, each participant was evaluated by
a clinical psychologist and completed a battery of neuropsychological assessments, as previously described [18]. The
Mini-Mental State Examination (MMSE) was used to determine
patients’ cognitive status, with an MMSE score of less than 26
indicating “cognitive impairment” and greater than 26 indicating “normal” cognition. The “Barratt Impulsivity Scale 11”
(BIS-11) was employed as a validated self-report questionnaire
for screening impulsivity. The BIS-11 consists of 30 questions
scored on a four-point scale, with each item corresponding to
one of the three BIS-11 second-order subscales. The current
study aimed to investigate cognitive domains of trait impulsivity
rather than motor impulsivity and therefore only BIS-11 secondorder attentional and nonplanning subscale scores are presented.
Questions corresponding to these subscales are summarised
in Table 1. Overall BIS-11 scores were calculated as the sum
of these 30 scores (to yield a score out of 120), with higher
scores indicating greater impulsivity. The sum of second-order
BIS-11 attentional and nonplanning items was used to calculate
patients’ BIS-11 second-order subscale scores. BIS-11 secondorder attentional and nonplanning scores were scored out of 32
and 44, respectively. During the screening process, patients
displaying any signs of an impulse control disorder were invited to seek further consultation with the clinical psychologist.
2.3. Statistical Methods. Data were analysed using IBM-SPSS
(v. 24, IBM Corporation). A signiﬁcant nominal p value of
<0.05 was employed. Univariate regression analysis of continuous demographic and clinical variables (MDS-UPDRS III,
disease duration, and LEDD) and categorical demographic
variables and clinical variables (gender, smoking history, level
of education, i.e., secondary school or tertiary education, and
cognitive status) was performed in order to determine whether
these variables were signiﬁcantly associated with BIS-11 secondorder attentional and nonplanning subscale scores. Level of
education was dichotomised into secondary school, referring to
participants who reported not progressing past secondary
school, and tertiary education, referring to participants who
reported entering into a tertiary level of education. Participants
who reported entering into a tertiary level of education were
considered as having a higher level of education.
General linear models (GLMs) were used to analyse the
relationship between variables identiﬁed as being signiﬁcant in
the univariate models and the two BIS-II second-order subscales. Variables proposed to be risk factors for the development of impulse control disorders in PD were also included
in the GLMs, despite not displaying statistical signiﬁcance in
the univariate models. Variables included in the GLMs were
gender, smoking history, dopamine agonist usage, LEDD, DBS
history, age at disease onset, disease duration, MDS-UPDRS
III scores, cognitive status, and participants’ level of education.
Nonsigniﬁcant variables were removed singularly in order of
least signiﬁcance until the ﬁnal models were determined.

3. Results
3.1. Cohort Information and Clinical Data. Mean demographic details and the results of clinical assessments are
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Table 1: Questions corresponding to BIS-11 second-order attentional and nonplanning domains.
BIS-11 2nd order subscale

Attentional impulsivity

Nonplanning impulsivity

shown in Table 2. The predominantly male cohort ranged in
age and disease duration. At the time of the study, a total of
45 participants were medicated with dopamine agonists
(DAs), and 14 participants had undergone DBS therapy.
When examined according to MMSE score, 70 patients did
not display cognitive impairment, and 17 were classiﬁed as
being cognitively impaired. Overall, the cohort displayed
a mean total BIS-11 score of 62.5 (±8.9) and had no prior
history of impulsivity, based on information provided
during consultation with a clinical psychologist.
3.2. Univariate Association of Demographic and Clinical
Variables with Second-Order Attentional and Nonplanning
Impulsivity. Univariate regression models revealed selected
clinical and demographic variables associated with BIS-11
second-order attentional scores including gender (p � 0.048)
and MDS-UPDRS III rating (p � 0.005). The residuals from
these univariate models were normally distributed. The patients’ level of education was positively associated with BIS-11
second-order attentional scores; however, this association did
not reach statistical signiﬁcance (p � 0.076). BIS-11 secondorder nonplanning scores were signiﬁcantly associated with
gender (p � 0.001), MDS-UPDRS III rating (p � 0.001), and
disease duration (p � 0.003). While the residual values of the
univariate models for MDS-UPDRS III rating and disease
duration were normally distributed, those for gender were not.
3.3. Demographic and Clinical Predictors of Second-Order
Attentional Impulsivity in Multivariate Models. Multivariate
general linear models were ﬁtted to identify demographic
and clinical determinants of BIS-11 second-order attentional
and nonplanning subscale scores. The residual values for these
multivariate models were normally distributed. Dopamine agonist
usage, LEDD, DBS surgery, age at onset, disease duration, and
cognitive status (cognitively impaired and not cognitively impaired) were found not to be signiﬁcant predictors of BIS-11

Corresponding questions
5. “I don’t pay attention”
6. “I have racing thoughts”’
9. “I concentrate easily”
11. “I squirm at plays or lectures”
20. “I am a steady thinker”
24. “I change hobbies”
26. “I often have extraneous thoughts when thinking”
28. “I am restless at the theatre or lectures”
1. “I plan tasks carefully”
7. “I plan trips well ahead of time”
8. “I am self controlled”
10. “I save regularly”
12. “I am a careful thinker”
13. “I plan for job security”
14. “I say things without thinking”
15. “I like to think about complex problems”
18. “I easily get bored when solving thought problems”
27. “I am more interested in the present than the future”
29. “I like puzzles”

Table 2: Baseline clinical characteristics of the PD cohort (n � 87)
used in this study.
Clinical characteristic
Gender
Male
Female
Age (years)
Age of onset (years)
Disease duration (years)
Dopamine agonist usage
Yes
No
LEDD (mg)
Deep brain stimulation
Yes
No
Smoking history
Yes
No
Level of education
Secondary school
Tertiary education
MDS-UPDRS III (motor)
Cognitive status
Cognitively impaired
Not cognitively impaired
BIS-11 scores
Attentional 2nd order
Nonplanning 2nd order
Total score

Mean (SD) or n (%)
54 (62%)
33 (38%)
62.8 (9.2)
53.3 (10.2)
10.4 (6.8)
45 (51.7%)
42 (48.3%)
671 (389)
14 (16.1%)
73 (83.9%)
13 (14.9%)
74 (85.1%)
58 (66.7%)
29 (33.3%)
18 (14.2)
22 (25.3%)
65 (74.7%)
15.8 (3.7)
24.8 (4.9)
62.5 (8.9)

second-order attentional or nonplanning subscale scores. In
contrast, being of male gender, no history of smoking, higher
level of education, and increased disease severity are predictive of elevated BIS-11 second-order attentional subscale
score when entered simultaneously in the model (Table 3).
Speciﬁcally, male participants were predicted to score
1.8 points higher than female participants (p � 0.011).
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Table 3: Final multivariate model parameter estimates: predictors
of BIS-11 second-order attention subscale scores.
Variable
(Intercept)
Gender
Male
Female
Smoking history
Yes
No
Level of education
Secondary school
Tertiary education
MDS-UPDRS III
∗

β coeﬃcient
12.537

Std. error
1.3095

p
0.000

1.730
0∗

0.7401
—

0.019
—

−2.207
0∗

1.0318
—

0.032
—

0∗
1.730
0.080

—
0.7581
0.0253

—
0.023
0.002

Comparison category set to zero.

The estimated marginal mean (EMM) BIS-11 attentional score
for male participants was 15.95 and 14.22 for female participants
(p � 0.019) (Figure 1). Patients with no smoking history were
predicted to score 2.2 points higher than those with a history of
smoking (p � 0.038), and patients who had pursued tertiary
studies were predicted to score 1.7 points higher than those who
had attained a secondary level of education (p � 0.023) on the
BIS-11 second-order attentional subscale. The EMM BIS-11
attentional score for those who undertook a secondary level
of education was 14.22 and 15.95 for those who pursued tertiary
studies (p � 0.023) (Figure 1). In addition to this, for every
additional MDS-UPDRS III point, BIS-11 second-order attentional scores were predicted to rise by 0.07 points (p � 0.003).
For example, a male patient who did not report a history of
smoking was predicted to score 2.2 points higher than a female
patient who did report a history of smoking.
3.4. Demographic and Clinical Predictors of Second-Order
Nonplanning Impulsivity in Multivariate Models. Similarly,
multivariate general linear models indicated that being of
male gender, greater level of education, and increased disease severity were predictive of elevated BIS-11 second-order
nonplanning subscale scores (Table 4). Smoking history was
not found to be a signiﬁcant determinant of nonplanning
subscale scores. Speciﬁcally, male participants were predicted to score three points higher than female participants
(p � 0.002). The EMM for BIS-11 nonplanning scores was
26.45 for male participants and 23.09 for female participants
(p � 0.001). Those who had pursued tertiary education
scored two points more than those who had attained
a secondary level of education (p � 0.047) on the BIS-11
second-order nonplanning subscale. The EMM for BIS-11
nonplanning scores was 23.79 for those who had attained
a secondary level of education and 25.76 for those who had
pursed tertiary education (p � 0.047) (Figure 1). In addition
to this, participants were predicted to score 0.1 points higher
for every additional MDS-UPDRS III score (p � 0.001) on
the BIS-11 second-order nonplanning subscale. For example, a patient who obtained an MDS-UPDRS III rating of 50
was predicted to score 3.3 points higher on the BIS-11
second-order nonplanning domain than a patient who
obtained an MDS-UPDRS III rating of 20.

4. Discussion
Several risk factors for the onset of ICDs in PD subjects have
been identiﬁed, including gender [11], smoking history
[11, 13, 14], history of drug or alcohol abuse [9, 15], impulsivity [9], and a novelty seeking personality [9, 15].
However, there are no established demographic or clinical
indicators for trait impulsivity in PD subjects. In light of the
close relationship between trait impulsivity and the development of ICDs, and in conjunction with the absence of
treatments for impulsive behaviours, there is a growing need
to identify risk factors associated with impulsivity. Our
ﬁndings suggest that several demographic and clinical
variables may underlie impulsive behaviours in PD subjects.
Aligning with previous ﬁndings regarding PD-ICD
subjects, the current study suggests that being of male
gender is a signiﬁcant risk factor for the development of trait
impulsivity [19, 20]. Male subjects displayed signiﬁcant
associations between disease severity and the BIS-11 secondorder attentional and nonplanning subscales. Regression
analysis revealed that male subjects were predicted to score
higher, particularly in the BIS-11 second-order nonplanning
subscale, when compared with female subjects. A similar
gender-related pattern of impulsive behaviour has been
demonstrated in both PD-ICD subjects and the general
population. For instance, Kenangil et al. [20] reported that
among a cohort of 554 PD patients, 33 had a diagnosed ICD,
of which 81% were men. In addition to this, male PD subjects
are more likely to develop pathological gambling and hypersexual behaviours than females, with a similar pattern
also evident in the general population [11].
This predisposition to developing impulsive behaviours
in males may be related to men historically requiring greater
stimulation and therefore being more likely to engage in
sensation-seeking and impulsive behaviours than females
[21]. Studies exploring gender diﬀerences in impulsivity
have underlined that whilst females display heightened
punishment sensitivity and are therefore more likely to avoid
danger or risk, males do not exhibit this trait which may
underlie the male propensity to partake in risky behaviours
and therefore display heightened impulsivity [22]. It is
important to note, however, that male PD subjects are less
likely to develop compulsive eating and shopping disorders
than female PD subjects, thus indicating that the type of
impulsive behaviour reported may be gender-speciﬁc [11].
To our knowledge, this is the ﬁrst study to explore the
inﬂuence of level of education on the development of impulsivity in PD. Given the association between lower education status and accelerated cognitive decline in PD, the
current study investigated whether achieving lower level of
education (i.e., ﬁnishing secondary school and not pursuing
tertiary studies) may also be related to elevated trait impulsivity [23]. However, the present study found that pursuing tertiary education and therefore pursuing education
after secondary school was a risk factor for elevated BIS-11
second-order attentional and nonplanning scores. Weintraub
et al. [11] identiﬁed a similar trend in a cohort of 3,090 PD
patients, with those diagnosed with an ICD more likely to have
more formal education. We suggest that seeking and obtaining
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Figure 1: Estimated marginal mean (EMM) BIS-11 second-order subscale scores. EMM BIS-11 (a) attentional and (b) nonplanning scores
were significantly higher in male subjects. EMM BIS-11 (c) attentional and (d) nonplanning scores were significantly higher in those who
had pursued tertiary education when compared with those who had attained a secondary level of education.

further education may reflect distortions in patients’ reward
processing, an important element of impulsivity, thereby
explaining this association between higher education status
and trait impulsivity. Neuroimaging studies have demonstrated that PD patients, particularly those taking dopaminergic medication or with a clinically diagnosed ICD, may
exhibit blunted reward anticipation and experiencing [24, 25].
In turn, these patients often make riskier choices in order to
compensate for this diminished reward response [24, 25].
Although seeking out additional education is not necessarily
an inherently risky process, it may nonetheless be related to
patients’ reduced ability to process and experience reward,
possibly leading to dissatisfaction with their current education
status and in turn, stimulating patients to pursue further
education opportunities with diminished disinhibition.
Heightened disease severity was also a significant determinant of elevated BIS-11 second-order attentional and
nonplanning scores in the described cohort, suggesting a relationship between more severe motor symptoms and future
trait impulsivity in PD. Indeed, previous studies have discounted disease severity as a risk factor for the development of
ICDs in PD subjects. Instead, these studies have underlined an
association between motor complications as measured by the
MDS-UPDRS IV and the future onset of ICDs, associating
this link with elevated dopaminergic loads as a result of
dopaminergic medication usage [26, 27]. Despite this, a more
recent investigation of impulsivity as a multidimensional
rather than unitary construct (i.e., ICD±) has reported a link

Table 4: Final multivariate model parameter estimates: predictors
of BIS-11 second-order nonplanning subscale scores.
Variable
(Intercept)
Gender
Male
Female
Level of education
Secondary school
Tertiary education
MDS-UPDRS III
∗

β coefficient
22.154

Std. error
1.0648

p
0.000

3.366
0∗

0.9680
—

0.001
—

—
0.9936
0.0328

—
0.047
0.001

0∗
1.971
0.106

Comparison category set to zero.

between elevated MDS-UPDRS III scores and impulsivity
in a cohort of 30 PD patients [6]. In this study, linear regression analysis verified that increased disease severity was
significantly associated with impaired performance on a variety of measures of impulsivity including the Frontal Assessment Battery, Stroop test, BIS-11, Stop-Signal Task (SST),
Go/No-Go task, and the Cambridge Gambling Task [6]. We
propose that the pathophysiological basis underlying this
association may be related to deteriorating motor symptoms
being reflective of progressive brain atrophy and dopaminergic
depletion, which, in turn, has been shown to have implications
for performance on a variety of measures of impulsivity and
therefore may contribute to the development of impulsive
behaviours [6].

6
Contrary to previous reports, an absence of past smoking
was a signiﬁcant risk factor for elevated BIS-11 second-order
nonplanning scores. Although a history of smoking has been
associated with the development of ICDs in PD subjects
[11, 13], our ﬁndings suggest otherwise with regard to
impulsivity, indicating an inverse relationship between past
smoking and trait impulsivity. However, given only 14
participants reported a history of smoking, this ﬁnding is
more likely attributed to the small sample size of smokers
included in the current cohort, as opposed to the presence of
a potential association between smoking history and
impulsivity.
A growing body of evidence exists to support the notion
that dopamine agonist [10] medication, administered to
alleviate the motor symptoms of PD in fact provokes ICDs in
PD subjects. DA usage has been associated with a 3.5-fold
increased risk of developing an ICD in PD patients [11].
Although the mechanism underlying this association remains unclear, the ability of DAs to stimulate dopamine
receptors in the striatal limbic system, an area involved in
reward and motivation, may contribute to the development
of reward-driven and compulsive behaviours exhibited by
PD patients with ICDs [28]. Interestingly, dopaminergic
medication was not a signiﬁcant determinant of trait impulsivity in this PD cohort. Though dopaminergic medication use has been associated with ICDs in PD cohorts, the
prevalence of ICDs in only a fraction of PD patients treated
with DAs highlights the importance of underlying susceptibility unrelated to dopaminergic medication use in the
development of impulsivity [11]. Further, a signiﬁcant
proportion of PD patients have been diagnosed with an ICD
before the initiation of any antiparkinsonian treatment,
supporting the notion of underlying individual susceptibility
to ICDs [8]. Therefore, the current ﬁnding further underlines
the importance of additional clinical and demographic factors
in the onset and development of impulsivity in PD.

5. Limitations
A number of limitations of the current study must be acknowledged. Firstly, the self-report nature of the BIS-11 may
introduce a degree of bias in the gathered responses due to
patients often being less inclined to report impulsive tendencies. Although the BIS-11 is frequently used as a measure
of impulsivity in PD studies, the BIS-11 was not originally
designed for use in a PD clinical setting, thereby somewhat
limiting the reliability of the BIS-11 second-order scales. As
the presence of depression or anxiety was not noted and
therefore patients with depression or anxiety were not actively excluded from the current study, the confounding
eﬀect of these psychiatric disorders on impulsivity outcomes
was not controlled for. In addition to this, patients’ cognitive
status was determined using an MMSE cutoﬀ score of 26,
which may not have accurately identiﬁed all patients
exhibiting signs of cognitive impairment. Further, available
data relating to the level of patient education indicated the
commencement of education after secondary school, but did
not necessarily provide information on study completion.
As such, this study cannot attribute tertiary education
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attainment to a rise in BIS-11 domain scores, rather the mere
pursuit of tertiary education.

6. Conclusion
In conclusion, the current study identiﬁed several demographic and clinical indicators of increased trait impulsivity in PD including male gender, heightened disease
severity, an absence of past smoking, and higher level of
education. The identiﬁcation of demographic and clinical
indicators of trait impulsivity in PD patients may serve as
a valuable clinical tool in facilitating the early recognition of
impulsivity and determining patients’ therapeutic regimen,
particularly regarding whether dopaminergic therapy may
provoke impulsive behaviours and likely ICDs in the future.

Conflicts of Interest
The authors declare that they have no conﬂicts of interest
regarding the publication of this article.

Acknowledgments
The study was funded by grant/research support from the
Federal Cooperative Research Centre for Mental Health, the
Perron Institute for Neurological and Translational Science,
and the University of Notre Dame Australia.

References
[1] L. U. Isaias, C. Siri, R. Cilia, D. De Gaspari, G. Pezzoli, and
A. Antonini, “The relationship between impulsivity and impulse control disorders in Parkinson’s disease,” Movement
Disorders, vol. 23, no. 3, pp. 411–415, 2008.
[2] J. W. Dalley, B. J. Everitt, and T. W. Robbins, “Impulsivity,
compulsivity, and top-down cognitive control,” Neuron, vol. 69,
no. 4, pp. 680–694, 2011.
[3] R. Cools, R. A. Barker, B. J. Sahakian, and T. W. Robbins, “LDopa medication remediates cognitive inﬂexibility, but increases impulsivity in patients with Parkinson’s disease,”
Neuropsychologia, vol. 41, no. 11, pp. 1431–1441, 2003.
[4] S. Gauggel, M. Rieger, and T. A. Feghoﬀ, “Inhibition of
ongoing responses in patients with Parkinson’s disease,”
Journal of Neurology, Neurosurgery & Psychiatry, vol. 75,
no. 4, pp. 539–544, 2004.
[5] I. Obeso, L. Wilkinson, E. Casabona et al., “Deﬁcits in inhibitory control and conﬂict resolution on cognitive and
motor tasks in Parkinson’s disease,” Experimental Brain
Research, vol. 212, no. 3, pp. 371–384, 2011.
[6] C. Nombela, T. Rittman, T. W. Robbins, and J. B. Rowe,
“Multiple modes of impulsivity in Parkinson’s disease,” PLoS
One, vol. 9, no. 1, article e85747, 2014.
[7] S. Rivaud-Pechoux, M. Vidailhet, J. P. Brandel, and B. Gaymard,
“Mixing pro- and antisaccades in patients with parkinsonian
syndromes,” Brain, vol. 130, no. 1, pp. 256–264, 2007.
[8] A. Antonini, C. Siri, G. Santangelo et al., “Impulsivity and
compulsivity in drug-naive patients with Parkinson’s disease,”
Movement Disorders, vol. 26, no. 3, pp. 464–468, 2011.
[9] V. Voon, M. Sohr, A. E. Lang et al., “Impulse control disorders
in Parkinson disease: a multicenter case–control study,”
Annals of Neurology, vol. 69, no. 6, pp. 986–996, 2011.

Parkinson’s Disease
[10] S. Y. Jeong and S. David, “Glycosylphosphatidylinositolanchored ceruloplasmin is required for iron eﬄux from
cells in the central nervous system,” Journal of Biological
Chemistry, vol. 278, no. 29, pp. 27144–27148, 2003.
[11] D. Weintraub, J. Koester, M. N. Potenza et al., “Impulse control
disorders in Parkinson disease: a cross-sectional study of 3090
patients,” Archives of Neurology, vol. 67, no. 5, pp. 589–595, 2010.
[12] A. A. Kehagia, C. R. Housden, R. Regenthal et al., “Targeting
impulsivity in Parkinson’s disease using atomoxetine,” Brain,
vol. 137, no. 7, pp. 1986–1997, 2014.
[13] G. T. Valenca, P. G. Glass, N. N. Negreiros et al., “Past
smoking and current dopamine agonist use show an independent and dose-dependent association with impulse
control disorders in Parkinson’s disease,” Parkinsonism &
Related Disorders, vol. 19, no. 7, pp. 698–700, 2013.
[14] A. H. Evans, A. D. Lawrence, J. Potts, S. Appel, and A. J. Lees,
“Factors inﬂuencing susceptibility to compulsive dopaminergic drug use in Parkinson disease,” Neurology, vol. 65,
no. 10, pp. 1570–1574, 2005.
[15] V. Voon, T. Thomsen, J. M. Miyasaki et al., “Factors associated
with dopaminergic drug-related pathological gambling in
Parkinson disease,” Archives of Neurology, vol. 64, no. 2,
pp. 212–216, 2007.
[16] J. H. Patton, M. S. Stanford, and E. S. Barratt, “Factor structure
of the Barratt impulsiveness scale,” Journal of Clinical Psychology, vol. 51, no. 6, pp. 768–774, 1995.
[17] M. S. Stanford, C. W. Mathias, D. M. Dougherty, S. L. Lake,
N. E. Anderson, and J. H. Patton, “Fifty years of the Barratt
impulsiveness scale: an update and review,” Personality and
Individual Diﬀerences, vol. 47, no. 5, pp. 385–395, 2009.
[18] T. Evans, A. Jeﬀerson, M. Byrnes et al., “Extended “timed up
and go” assessment as a clinical indicator of cognitive state in
Parkinson’s disease,” Journal of the Neurological Sciences,
vol. 375, pp. 86–91, 2017.
[19] R. Anderton, M. Byrnes, A. Jeﬀerson et al., “Sleep disturbance
and serum ferritin levels associate with high impulsivity and
impulse control disorders in male Parkinson’s disease patients,” American Journal of Psychiatry and Neuroscience,
vol. 5, no. 4, p. 45, 2017.
[20] G. Kenangil, S. Ozekmekci, M. Sohtaoglu, and E. Erginoz,
“Compulsive behaviors in patients with Parkinson’s disease,”
Neurologist, vol. 16, no. 3, pp. 192–195, 2010.
[21] T. L. Waldeck and L. S. Miller, “Gender and impulsivity
diﬀerences in licit substance use,” Journal of Substance Abuse,
vol. 9, pp. 269–275, 1997.
[22] C. P. Cross, L. T. Copping, and A. Campbell, “Sex diﬀerences in
impulsivity: a meta-analysis,” Psychological Bulletin, vol. 137, no. 1,
pp. 97–130, 2011.
[23] J. Meireles and J. Massano, “Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and
management,” Frontiers in Neurology, vol. 3, p. 88, 2012.
[24] J. Riba, U. M. Kramer, M. Heldmann, S. Richter, and
T. F. Munte, “Dopamine agonist increases risk taking but
blunts reward-related brain activity,” PLoS One, vol. 3, no. 6,
article e2479, 2008.
[25] Z. Ye, A. Hammer, E. Camara, and T. F. Munte, “Pramipexole
modulates the neural network of reward anticipation,” Human Brain Mapping, vol. 32, no. 5, pp. 800–811, 2011.
[26] D. J. Ahearn, K. McDonald, M. Barraclough, and I. Leroi, “An
exploration of apathy and impulsivity in Parkinson disease,”
Current Gerontology and Geriatrics Research, vol. 2012, article
390701, 10 pages, 2012.
[27] I. Leroi, M. Andrews, K. McDonald et al., “Apathy and impulse control disorders in Parkinson’s disease: a direct

7
comparison,” Parkinsonism & Related Disorders, vol. 18, no. 2,
pp. 198–203, 2012.
[28] A. Hassan, J. H. Bower, N. Kumar et al., “Dopamine agonisttriggered pathological behaviors: surveillance in the PD clinic
reveals high frequencies,” Parkinsonism & Related Disorders,
vol. 17, no. 4, pp. 260–264, 2011.

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com
www.hindawi.com

Volume 2018
2013

Gastroenterology
Research and Practice
Hindawi
www.hindawi.com

Volume 2018

Journal of

Hindawi
www.hindawi.com

Diabetes Research
Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi
www.hindawi.com

Disease Markers

Hindawi
www.hindawi.com

Volume 2018

Volume 2018

Submit your manuscripts at
www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi
www.hindawi.com

Hindawi
www.hindawi.com

Volume 2018

Volume 2018

Journal of

Obesity

Journal of

Ophthalmology
Hindawi
www.hindawi.com

Volume 2018

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Journal of

Oncology
Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2013

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi
www.hindawi.com

Volume 2018

AIDS

Behavioural
Neurology
Hindawi
www.hindawi.com

Research and Treatment
Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Hindawi
www.hindawi.com

Volume 2018

Oxidative Medicine and
Cellular Longevity
Hindawi
www.hindawi.com

Volume 2018

